Asset
PRALICIGUAT
AKEBIA THERAPEUTICS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07268638 | phase2 | recruiting | 2025-12-03 | 2027-06-01 | Akebia Therapeutics | A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS) |
| NCT03254485 | phase2 | completed | 2017-11-07 | 2019-08-19 | Akebia Therapeutics | A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) |
| NCT03217591 | phase2 | completed | 2017-08-01 | 2019-08-20 | Akebia Therapeutics | A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria |
FDA applications (0)
This company has no applications containing this asset.